The Motley Fool·1d ago
Is Regeneron Stock a Bargain Below $800?Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff.
Regeneron's growth has decelerated to low-single digits, with revenue growth of 16.7% in 2026Q2 masking a 3.7% decline in 2025Q1, while gross margins have compressed from 86.8% in 2024Q3 to 81.2% in 2026Q2. The company maintains a fortress balance sheet with a...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 16.7% in 2026Q2 but was negative in 2025Q1 (-3.7%), while gross margin slipped 560 basis points from 86.8% to 81.2% over the period.
Regeneron focuses on discovering and developing medicines for serious medical conditions, indicating a robust pipeline of potential treatments.
The company maintains a dedicated Investor Relations website, showcasing transparency and engagement with stockholders and analysts.
As a long-standing biotech firm since 1988, Regeneron has established expertise in developing and commercializing innovative therapies.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $14.29+40.6% vs $10.16 | $4.3B+12.4% vs $3.8B |
Q2 2026 Apr 29, 2026 | $9.47+6.3% vs $8.91 | $3.6B+3.6% vs $3.5B |
Q1 2026 Jan 30, 2026 | $11.44+6.5% vs $10.74 | $3.9B+1.9% vs $3.8B |
Q4 2025 Oct 28, 2025 | $11.83+22.6% vs $9.65 | $3.8B+4.5% vs $3.6B |
Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff.
Corient Private Wealth LP lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 31.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,473 shares of the biopharmaceutical company's stock after selling 5,600 shares during the period. Corient
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
Benchmark REGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Regeneron Pharmaceuticals, Inc. (REGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $803.90 | $82.82B | 19.38 | 0.99% | 31.41% | 14.87% | 0.42% | |
| $225.36 | $33.3B | 25.52 | 1.39% | 8.39% | 4.52% | — | |
| $514.99 | $130.71B | 33.62 | 9.57% | 34.89% | 23.31% | — | |
| $126.93 | $25.73B | 19.80 | 21.22% | 27.71% | 29.7% | — | |
| $63.37 | $12.25B | 35.21 | 12.87% | 2.14% | 1.18% | — | |
| $265.32 | $468.77B | 111.95 | 8.57% | 9.81% | — | — |
Regeneron Pharmaceuticals, Inc. (REGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Regeneron Pharmaceuticals, Inc. (REGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 6, 2026·SEC
Jun 17, 2026·SEC
Get notified when REGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Regeneron Pharmaceuticals, Inc. (REGN) stock FAQ — growth, dividends, profitability & financials explained
Regeneron Pharmaceuticals, Inc. (REGN) reported $15.53B in revenue for fiscal year 2025. This represents a 64359% increase from $24.1M in 1996.
Regeneron Pharmaceuticals, Inc. (REGN) grew revenue by 1.0% over the past year. Growth has been modest.
Yes, Regeneron Pharmaceuticals, Inc. (REGN) is profitable, generating $4.33B in net income for fiscal year 2025 (31.4% net margin).
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend with a yield of 0.42%. This makes it attractive for income-focused investors.
Regeneron Pharmaceuticals, Inc. (REGN) has a return on equity (ROE) of 14.9%. This is reasonable for most industries.
Regeneron Pharmaceuticals, Inc. (REGN) generated $3.52B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
